🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are escalating globally, with data suggesting over 82 million new cases annually. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This milestone signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Outcomes and Global Access

Based on findings detailed in a major medical journal, zoliflodacin cured more than 90% of cases of the STI. This establishes an comparable level with the existing first-line therapy, which combines a dual-drug approach. The study included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have shared hope. Access to a one-pill regimen like this is described as a "game-changer" for public health efforts. This is deemed essential to alleviate the strain of the infection for people and to stop the proliferation of extremely resistant gonorrhoea around the world.